Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 17;15(1):109.
doi: 10.1038/s41408-025-01296-8.

A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)

Chandramouli Nagarajan #  1   2 , Wei-Ying Jen #  3   4 , Melissa Ooi  3 , Sanjay De Mel  3 , Cinnie Soekojo  3 , Sung Soo Yoon  5 , Melinda Tan  1   2 , Yunxin Chen  1   2 , Xinhua Li  6 , Yogesh Pokharkar  6 , Shi Ning Tham  1 , Nur Shahidah Binte Hashim  1 , Neha Awasthi  6 , Sarah M Burkill  6 , Brian Durie  7 , Wee Joo Chng  8   9
Affiliations

A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)

Chandramouli Nagarajan et al. Blood Cancer J. .

Abstract

NCT03153036.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethical approval: All patients provided informed consent before trial entry. The trial was approved by institutional IRBs of all participating centres. The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.

Figures

Fig. 1
Fig. 1
Consort Diagram and Patient Disposition.
Fig. 2
Fig. 2
Progression free survival of evaluable patients treated with DTd.
Fig. 3
Fig. 3
Overall survival of evaluable patients treated with DTd.
Fig. 4
Fig. 4
Forest plot of subgroup analysis for ORR.
Fig. 5
Fig. 5
Forest plot for subgroup analysis for PFS.
See this image and copyright information in PMC

References

    1. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43:676–81. - PMC - PubMed
    1. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl J Med. 2016;375:754–66. - PubMed
    1. Dimopoulos MA, Terpos E, Boccadoro M, Delimpasis S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:801–12. - PubMed
    1. Hideshima T, Ogiya D, Liu J, Harada T, Kurata K, Bae J, et al. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways. Leukemia. 2021;35:177–88. - PMC - PubMed
    1. Naeimi Kararoudi M, Nagai Y, Elmas E, Fernandes Pereira MDS, Abbas Ali S, Imus PH, et al. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020;136:2416–27. - PMC - PubMed

MeSH terms